Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antares Pharma, Inc.

http://www.antarespharma.com/

Latest From Antares Pharma, Inc.

Assertio Targets Febrile Neutropenia Drug In Spectrum Buyout Deal

It remains unclear whether Rolvedon will achieve hoped-for sales milestones in a deal that Assertio said was part of a growth strategy emphasizing product and business acquisitions.

Deals M & A

Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking

China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.

China Leadership

Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence

The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

Scrip Asks Artificial Intelligence

Scrip Asks...What Does 2023 Hold For Biopharma? Part 1: The Funding Environment

With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.

Scrip Asks Financing
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
      • Transdermal
  • Other Names / Subsidiaries
    • Halozyme Therapeutics, Inc.
    • Medi-Ject Corporation
    • Permatec
UsernamePublicRestriction

Register